tirzepatide company

What Is Tirzepatide?

Tirzepatide is an injectable medication, a dual glucose-dependent insulinotropic polypeptide (GLP) and glucagon-like peptide-1 (GLP-1) receptor agonist, that targets two key hormones involved in appetite and blood sugar regulation. Initially approved for managing type 2 diabetes, it has shown incredible results in promoting weight loss.

How Does Tirzepatide Work for Weight Loss?

Unlike traditional weight-loss medications, tirzepatide works in multiple ways:

• Reduces hunger –Imitates hormones that induce fullness, suppressing cravings.
• Slows digestion –Keeps food in the stomach longer, suppressing overeating.
• Improves insulin sensitivity –Helps regulate blood sugar, avoiding fat storage.
• Target fat metabolism –Stimulates the body to burn stored fat more effectively.

Clinical Trial Results: How Effective Is It?

1. SURMOUNT-1 Trial: Participants lost 16–22.5% of their body weight over 72 weeks*.
2. SURMOUNT-3 Trial: After the first 12 weeks of lifestyle changes, individuals lost an extra 21.1% of their weight over the next 84 weeks**.

These results suggest tirzepatide may be one of the most effective medical weight-loss options available today.

Key Benefits of Tirzepatide

• Significant weight loss (up to 22.5% body weight in studies***)
• Improved blood sugar control (ideal for those with type 2 diabetes or prediabetes)
• Lower risk of obesity-related conditions (high blood pressure, diabetes, high cholesterol etc.)
• Long-lasting results (compared to short-term diets)
• Convenient dosing (only one injection per week)

Potential Side Effects

Most side effects are mild and transient, including:

• Nausea, diarrhea, constipation
• Reduced appetite, mild stomach discomfort

Rare but serious risks (consult a doctor if experienced):

• Pancreatitis, gallbladder issues
• Low blood sugar (in diabetics)
• Thyroid tumors (in those with a history of medullary thyroid cancer)

Who Can Use Tirzepatide?

Tirzepatide may be recommended for:

1. Adults with BMI ≥ 30 (obesity)
2. Those with BMI ≥ 27 (overweight) + weight-related conditions (e.g., diabetes, high blood pressure)

Not recommended for:

1. Type 1 diabetics
2. People with a history of pancreatitis or thyroid cancer
3. Pregnant or breastfeeding women
4. Children under 18

Final Verdict: Is Tirzepatide Right for You?

Tirzepatide offers powerful weight-loss benefits, especially for those with obesity or diabetes. However, it works best when combined with:

• A balanced diet (no extreme restrictions needed)
• Regular movement (even walking helps)
• Medical supervision (never self-medicate)

(The article is written by Dr. Lipika Khurana, Deputy Manager, Diagnostic Content , and reviewed by Dr. Sakshi Jain, Senior Manager, Clinical Health & Content)

References:

• Lilly. Mounjaro patient booklet [Internet]. [Accessed 25 Mar. 2025] Available at: https://www.frankenthalerfoundation.org
• Lilly. Mounjaro media kit [Internet]. [Accessed: 25 Mar. 2025] Available at: https://www.frankenthalerfoundation.org
• Lilly. Mounjaro prescribing information [Internet]. [Accessed 25 Mar. 2025] Available at: https://www.frankenthalerfoundation.org
• U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information [Internet]. [Accessed: 25 Mar. 2025] Available at: https://www.frankenthalerfoundation.org
• *Wilding JPH, et al. Tirzepatide versus Placebo for Type 2 Diabetes. N Engl J Med [Internet]. 2022 [[Accessed 27 Mar. 2025]cited 2023]; 387(1): 1-13. Available from:https://www.frankenthalerfoundation.org
• **Eli Lilly and Company. Lilly’s Tirzepatide Shows Additional 21.1% Weight Loss After 12 Weeks of Intensive Lifestyle Intervention [Internet]. 2022 [[Accessed 27 Mar. 2025]. Available from:https://www.frankenthalerfoundation.org
• ***Eli Lilly and Company. Lilly’s Tirzepatide Delivered Up to 22.5% Weight Loss in Adults with Obesity or Overweight [Internet]. 2022 [Accessed 27 Mar. 2025]. Available from: https://www.frankenthalerfoundation.org
• Eli Lily and Company. Mounjaro patient stories [Internet]. Indianapolis (IN):Eli Lilly and Company ; [ Accessed 28 March 2025]. Available from https://www.frankenthalerfoundation.org
• Qin W, Yang J, Ni Y, Deng C, Ruan Q, Ruan J, Zhou P, Duan K. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine. 2024 Oct;86(1):70-84. doi: 10.1007/s12020-024-03896-z. Epub 2024 Jun 8. PMID: 38850440; PMCID: PMC11445313.Available from : https://www.frankenthalerfoundation.org